JP2018537536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537536A5 JP2018537536A5 JP2018549407A JP2018549407A JP2018537536A5 JP 2018537536 A5 JP2018537536 A5 JP 2018537536A5 JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018537536 A5 JP2018537536 A5 JP 2018537536A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic composition
- cells
- composition according
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265382P | 2015-12-09 | 2015-12-09 | |
| US62/265,382 | 2015-12-09 | ||
| PCT/US2016/066018 WO2017100709A1 (en) | 2015-12-09 | 2016-12-09 | Compositions and methods for treatment of her2 positive metastatic breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537536A JP2018537536A (ja) | 2018-12-20 |
| JP2018537536A5 true JP2018537536A5 (enExample) | 2019-12-12 |
Family
ID=59013368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549407A Pending JP2018537536A (ja) | 2015-12-09 | 2016-12-09 | Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180360881A1 (enExample) |
| EP (1) | EP3386522A4 (enExample) |
| JP (1) | JP2018537536A (enExample) |
| KR (1) | KR20180123214A (enExample) |
| CN (1) | CN109475576A (enExample) |
| AU (1) | AU2016366677A1 (enExample) |
| CA (1) | CA3007996A1 (enExample) |
| WO (1) | WO2017100709A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4650005A3 (en) | 2016-07-15 | 2026-01-28 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| CN110769898A (zh) * | 2017-06-22 | 2020-02-07 | 南加利福尼亚大学 | 使用嵌合抗原受体工程化自然杀伤细胞作为化学治疗药物运载体的联合癌症疗法 |
| US11510982B2 (en) | 2017-08-15 | 2022-11-29 | Nantcell, Inc. | HaNK cetuximab combinations and methods |
| CN110484507B (zh) * | 2018-01-31 | 2023-10-13 | 温州医科大学 | 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术 |
| IL321548A (en) * | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| BR112021001750A2 (pt) * | 2018-08-06 | 2021-04-27 | Daiichi Sankyo Company, Limited | composição farmacêutica |
| KR20240162586A (ko) * | 2018-10-31 | 2024-11-15 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거 |
| US20220265716A1 (en) * | 2019-07-26 | 2022-08-25 | Nantkwest, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN112675313A (zh) * | 2020-12-28 | 2021-04-20 | 烟台大学 | 连接曲妥珠单抗片段的美登素纳米粒组合物 |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040105740A (ko) * | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| JP5295568B2 (ja) * | 2005-01-06 | 2013-09-18 | ノヴォ ノルディスク アー／エス | Ｋｉｒ結合剤およびその使用方法 |
| JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| EP3701957B1 (en) * | 2013-11-01 | 2022-12-28 | ImmunityBio, Inc. | Tumoricidal and antimicrobial compositions and methods |
| CN113699159A (zh) * | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
| CA2980592A1 (en) * | 2015-03-27 | 2016-10-06 | Nantkwest, Inc. | Nk-92 cells in combination therapy with cancer drugs |
-
2016
- 2016-12-09 AU AU2016366677A patent/AU2016366677A1/en not_active Abandoned
- 2016-12-09 CA CA3007996A patent/CA3007996A1/en active Pending
- 2016-12-09 US US15/781,428 patent/US20180360881A1/en not_active Abandoned
- 2016-12-09 WO PCT/US2016/066018 patent/WO2017100709A1/en not_active Ceased
- 2016-12-09 JP JP2018549407A patent/JP2018537536A/ja active Pending
- 2016-12-09 CN CN201680080518.8A patent/CN109475576A/zh active Pending
- 2016-12-09 EP EP16874010.8A patent/EP3386522A4/en not_active Withdrawn
- 2016-12-09 KR KR1020187019391A patent/KR20180123214A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Herrera et al. | Bispecific antibodies: advancing precision oncology | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Albayrak et al. | T cell engagers: expanding horizons in oncology and beyond: translational therapeutics | |
| Shabaneh et al. | Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity | |
| Dees et al. | Bispecific antibodies for triple negative breast cancer | |
| Vacchelli et al. | Trial watch: Monoclonal antibodies in cancer therapy | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| JP2019513777A5 (enExample) | ||
| Vyas et al. | Antigen loss variants: catching hold of escaping foes | |
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| CN111886015B (zh) | 用于同种异体嵌合抗原受体t细胞的给药的方法和组合物 | |
| Patriarca et al. | Investigational drugs for the treatment of diffuse large B-cell lymphoma | |
| Kamakura et al. | T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity | |
| JP2017507936A5 (enExample) | ||
| Attarwala | Role of antibodies in cancer targeting | |
| JP2018529327A5 (enExample) | ||
| JP2016187356A5 (enExample) | ||
| JP2016513458A5 (enExample) | ||
| JP2015517470A5 (enExample) | ||
| Bergamaschi et al. | Innovative strategies for T cell engagers for cancer immunotherapy | |
| Pulido et al. | Hopes on immunotherapy targeting B7-H3 in neuroblastoma | |
| Saini et al. | Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment |